Wednesday 20 August 2014

Novartis hands over experimental TB drugs in antibiotic pullback

Logo of Swiss drugmaker Novartis is seen at its headquarters in Basel By Caroline Copley ZURICH (Reuters) - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics. The TB Alliance deal reflects renewed scrutiny of the Novartis portfolio under new chairman Joerg Reinhardt, who is focusing the Swiss company's research on core areas such as cancer, respiratory drugs, heart failure and dermatology. "Novartis is not really focused on anti-infectives, so I think it makes sense," Kepler Cheuvreux analyst Fabian Wenner said of the licensing deal. Under the terms of Wednesday's agreement, TB Alliance will fund further research and development and be responsible for seeking approval and commercializing the TB treatments discovered at the Novartis Institute for Tropical Disease.




via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment